Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + filgrastim + fluorouracil + interferon alfa
- Development stage
- Preclinical
- Lead developer
- Michigan State University
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
This is a combination chemotherapy regimen that includes cisplatin (a platinum-based chemotherapeutic agent), filgrastim (a granulocyte colony-stimulating factor), fluorouracil (a pyrimidine analog), and interferon alfa (an immunomodulatory cytokine). The combination is used in the treatment of advanced cancers. Fluorouracil (5-FU) and interferon alfa have shown synergistic effects in treating hepatocellular carcinoma and colorectal cancer. The addition of cisplatin provides platinum-based cytotoxicity, while filgrastim helps manage neutropenia associated with chemotherapy.
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)IFNAR (Immune system modulation via type I interferon receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + filgrastim + fluorouracil + interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + filgrastim + fluorouracil + interferon alfa.